Currently MAPK pathway inhibitors, including BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (trametinib, cobimetinib), are the only mutation-specific, targeted therapies currently approved for melanoma patients. Here, MAP2K7 is linked to melanoma.